Beta Bionics, Inc. (BBNX)
NASDAQ: BBNX · Real-Time Price · USD
15.90
-0.85 (-5.07%)
Nov 2, 2026, 4:00 PM EST - Market closed
Beta Bionics Balance Sheet
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Assets
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 |
Cash & Equivalents | 81.55 | 31.58 | 30.43 | 26.57 | 27.68 |
Short-Term Investments | 158.65 | 187.55 | 73.14 | 70.18 | - |
Cash & Short-Term Investments | 240.2 | 219.13 | 103.58 | 96.75 | 27.68 |
Cash Growth | 5.04% | 111.56% | 7.06% | 249.58% | - |
Accounts Receivable | 20.67 | 17.12 | 12 | 4.45 | - |
Other Receivables | 3.08 | 2.78 | 1.05 | - | - |
Receivables | 23.75 | 19.89 | 13.05 | 4.45 | - |
Inventory | 22.97 | 21.72 | 13.32 | 1.25 | - |
Prepaid Expenses | 5.92 | 7.06 | 2.98 | 0.91 | 0.54 |
Restricted Cash | 0.1 | 0.1 | - | - | - |
Other Current Assets | - | - | - | 0.28 | 0.25 |
Total Current Assets | 292.95 | 267.91 | 132.92 | 103.62 | 28.47 |
Property, Plant & Equipment | 17.17 | 15.23 | 11.42 | 6.2 | 6.87 |
Long-Term Investments | 133.44 | 45.43 | - | - | - |
Long-Term Deferred Charges | - | - | 5.05 | - | - |
Other Long-Term Assets | 0.21 | 0.18 | 0.25 | 0.22 | 0.19 |
Total Assets | 443.76 | 328.74 | 149.65 | 110.04 | 35.53 |
Liabilities
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 |
Accounts Payable | 4.68 | 5 | 2.85 | 1.17 | 0.43 |
Accrued Expenses | 18.58 | 17.34 | 13.33 | 7.07 | 6.14 |
Current Portion of Leases | 1.45 | 1.94 | 1.53 | 1.22 | 0.98 |
Current Unearned Revenue | 2.05 | 1.56 | 0.94 | 0.09 | - |
Other Current Liabilities | 6.08 | 5.1 | 2.5 | 1.05 | 1.32 |
Total Current Liabilities | 32.84 | 30.92 | 21.15 | 10.61 | 8.87 |
Long-Term Leases | 4.65 | 5.37 | 5.73 | 3 | 3.16 |
Long-Term Unearned Revenue | 3.48 | 3.3 | 1.86 | 0.26 | - |
Other Long-Term Liabilities | 1.41 | 1.55 | 44.9 | 37.57 | 10.5 |
Total Liabilities | 42.38 | 41.13 | 73.63 | 51.43 | 22.53 |
Shareholders' Equity
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 |
Common Stock | 0.01 | 0 | 0 | 0 | 0 |
Additional Paid-In Capital | 841.84 | 657.14 | 51.31 | 26.42 | 15.53 |
Retained Earnings | -439.59 | -369.94 | -296.74 | -229.66 | -185.57 |
Comprehensive Income & Other | -0.88 | 0.4 | 0.07 | 0.14 | - |
Total Common Equity | 401.38 | 287.61 | -245.36 | -203.11 | -170.03 |
Shareholders' Equity | 401.38 | 287.61 | 76.01 | 58.61 | 13 |
Total Liabilities & Equity | 443.76 | 328.74 | 149.65 | 110.04 | 35.53 |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 |
Total Debt | 6.1 | 7.3 | 7.26 | 4.22 | 4.13 |
Net Cash (Debt) | 234.1 | 211.82 | 96.32 | 92.52 | 23.54 |
Net Cash Growth | 5.93% | 119.91% | 4.11% | 293.01% | - |
Net Cash Per Share | 5.20 | 5.23 | 15.13 | 17.44 | 4.71 |
Filing Date Shares Outstanding | 54.37 | 44.38 | 43.35 | 5.03 | 5 |
Total Common Shares Outstanding | 54.36 | 44.36 | 6.67 | 5.03 | 5 |
Working Capital | 260.11 | 236.98 | 111.78 | 93.02 | 19.59 |
Book Value Per Share | 7.38 | 6.48 | -36.80 | -40.39 | -34.02 |
Tangible Book Value | 401.38 | 287.61 | -245.36 | -203.11 | -170.03 |
Tangible Book Value Per Share | 7.38 | 6.48 | -36.80 | -40.39 | -34.02 |
Machinery | 14.89 | 10.19 | 7.48 | 5.78 | 5.56 |
Construction In Progress | 1.96 | 3.34 | 1.74 | 0.17 | 0.18 |
Leasehold Improvements | 2.86 | 0.83 | 0.81 | 0.95 | 0.95 |